PsoriasisPro Clinical Highlights

PsoriasisPro Clinical Highlights feature key opinion leaders in the field of dermatology. These 5- to 10-minute clinical presentations are designed to inform you of the latest developments and treatment protocols, and serve to be an informative and educational resource for your practice. You can also view a 30-second preview of each presentation by clicking the thumbnails below.

Emil A. Tanghetti, MD

The Emerging Role of Vitamin D in Dermatology

Presented by Emil A. Tanghetti, MD

Conventional ideas regarding the origins of psoriasis are changing, and a different treatment paradigm is emerging. This presentation highlights key findings regarding the pathogenesis of psoriasis, benefits and risks of corticosteroids and how Vitamin D3 can help manage the cycle of symptoms long term.

View Presentation
Jerry Bagel, MD

Initiation of Topical Vitamin D3 Ointment for Long-term Management of Psoriasis

Presented by Jerry Bagel, MD

The pathogenesis of psoriasis is multifactorial, and like any multifactorial disease, treatments should be designed to combat several, if not all, factors simultaneously. This presentation discusses the value of initiating therapy with topical Vitamin D3 ointment to regulate epidermal cell differentiation and reduce the recurrence of plaques in adult patients with mild to moderate plaque psoriasis.

View Presentation
Helen Torok, MD

Sustained Use of Vectical® (calcitriol) Ointment 3 µg/g to Help Delay Plaque Recurrence

Presented by Helen Torok, MD

Psoriasis is a chronic disease that requires long-term management. Topical Vitamin D3 treatments such as Vectical® (calcitriol) Ointment 3 µg/g have been shown to help address abnormal differentiation in psoriatic skin, a factor contributing to plaque recurrence. This clinical highlight describes the unique benefits of topical Vitamin D3 and data that support its sustained use in the treatment of psoriasis.

View Presentation
Leon Kircik, MD

Clobex® Spray Versus Taclonex® Ointment: An Evaluation of the Efficacy and Safety of Clobex® (clobetasol propionate) Spray, 0.05%, and Taclonex® (calcipotriene 0.005%; betamethasone dipropionate 0.064%) Ointment in Subjects With Stable Plaque Psoriasis

Presented by Leon Kircik, MD

Topical steroids are a mainstay in the treatment of psoriasis. This clinical highlight describes the outcomes of a clinical study comparing 2 frequently used topical treatments, Clobex® (clobetasol propionate) Spray, 0.05%, and Taclonex® (calcipotriene 0.005%/betamethasone dipropionate 0.064%) Ointment, for the treatment of moderate to severe plaque psoriasis.

View Presentation
Fran Cook-Bolden, MD

Clobex® (clobetasol propionate) Spray, 0.05%: A Novel Topical Treatment for Scalp Psoriasis

Presented by Fran Cook-Bolden, MD

Plaque psoriasis of the scalp can be a burdensome condition that is difficult to treat. This clinical highlight describes the outcomes of a clinical study evaluating the use of Clobex® (clobetasol propionate) Spray, 0.05%, for the treatment of moderate to severe plaque psoriasis of the scalp.

View Presentation

Next: The Emerging Role of Vitamin D in Dermatology

Featured Presentations

View presentations from national thought leaders in the treatment of psoriasis.

View Now

An Important Resource From Galderma

Receive a copy of Contemporary Diagnosis and Management of Psoriasis, featuring John Koo, MD, Judith Hong, MD, and Tina Bhutani, MD.

Learn More